STOCKHOLM, Jan 31, 2017 /PRNewswire/ --
During December, the number of shares and votes in Alligator Bioscience AB (publ) has increased due to that 700,000 warrants in the warrant program 2014/2017 issued pursuant to the resolution by the extraordinary shareholders' meeting on 5 November 2013 have been excercised for subscription of 700,000 new shares. As of January 31, 2017, the number of shares and votes in Alligator Bioscience AB amounts to 70,813,615.
Alligator is a research-based biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company is headquartered in Lund, Sweden, and had 35 employees per December 31, 2016. The Company is primarily active in the early stages of drug development, from the idea stage to clinical phase IIa studies, and Alligator's product portfolio primarily consist of the product candidates ADC-1013, ATOR-1015 and ATOR-1016. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The company's shares are listed on Nasdaq Stockholm under the ticker "ATORX". For more information, visit www.alligatorbioscience.com.
For further information, please contact:
Per Norlén, CEO
Telephone: + 46 46 286 42 80 (switchboard)
Rein Piir, VP Investor Relations
Telephone: +46 708 53 72 92
The information in the press release is such that Alligator Bioscience AB is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on January 31, 2017.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Alligator Bioscience